Retatrutide
Also known as: LY3437943, Triple G
Buy in shop
Retatrutide from $81/kit
3 verified vendors, ≥99% purity, COAs included.
Key Facts: Retatrutide
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Phase 3 Clinical Trials - TRIUMPH-4 (Dec 2025): 28.7% mean weight loss, highest ever in obesity trial. NDA expected Q4 2026-Q1 2027
- Administration
- Subcutaneous injection weekly
- Typical Dose
- 4-12 mg weekly
- Frequency
- Once weekly, same day each week
- Duration
- Long-term use expected
Mechanism of Action
Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects.
Research Summary
Phase 3 TRIUMPH-4 trial (Dec 2025) showed 28.7% weight loss at 68 weeks, with average loss of 71 lbs. Also showed significant osteoarthritis pain relief, reduced cardiovascular risk markers, and 14 mmHg blood pressure reduction. Seven more Phase 3 readouts expected in 2026. NDA submission expected late 2025/early 2026. First Phase 3 results (TRIUMPH-4, Dec 2025) showed 28.7% mean weight loss at 68 weeks with the 12mg dose - the highest ever reported in an obesity clinical trial (average 71.2 lbs / 32.3 kg lost). Seven more Phase 3 trials expected to report throughout 2026.
Dosing Information
Typical Dosingⓘ
Community experience
4-12 mg weekly
1-12 mg weekly (titrate up slowly)
Once weekly, same day each week
Triple agonist (GLP-1/GIP/glucagon). Start low (1-2 mg) and titrate up to minimize GI side effects. Not yet FDA approved but available through compounding.
Research Dosingⓘ
Scientific studies
Doses from clinical trials
Doses from Studies
0.5mg weekly (starting)
Phase 2 T2D Trial, Lancet 2023 - 0.5mg maintenance arm with no escalation ↗
4mg weekly (maintenance)
8mg weekly (maintenance)
12mg weekly (highest studied)
Phase 2 Obesity Trial, NEJM 2023 - Maximum dose showing 24% weight loss ↗
Duration
Long-term use expected
Administration
Subcutaneous injection weekly
Timing & Administration
Best Time to Take
Morning, same day each week
Once weekly, same day and time
Food Recommendation
With or without food
Why This Timing?
As a triple agonist, consistent weekly timing is important. Morning allows for side effect monitoring.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (dose-related)
- ●Diarrhea
- ●Vomiting
- ●Constipation
- ●Heart rate increases
- ●Hypersensitivity reactions
- ●Dysesthesia - skin sensitivity/tingling (~21% at highest dose, TRIUMPH-4 data)
- ●Pancreatitis (rare)
- ●Currently in Phase 3 trials
References
- https://pubmed.ncbi.nlm.nih.gov/37366315/
- https://pubmed.ncbi.nlm.nih.gov/37385280/
- https://clinicaltrials.gov/study/NCT04881760
Research This Peptide Further
Buy in shop
Retatrutide from $81/kit
3 verified vendors, ≥99% purity, COAs included.
Frequently Asked Questions
What does Retatrutide do?
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
How does Retatrutide work?
Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects.
Is Retatrutide FDA approved?
No, Retatrutide is not currently FDA approved. Current status: Phase 3 Clinical Trials - TRIUMPH-4 (Dec 2025): 28.7% mean weight loss, highest ever in obesity trial. NDA expected Q4 2026-Q1 2027
What are the side effects of Retatrutide?
Reported side effects include: Nausea (dose-related), Diarrhea, Vomiting, Constipation, Heart rate increases. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Retatrutide?
Community-reported common dose: 4-12 mg weekly (Once weekly, same day each week). Range: 1-12 mg weekly (titrate up slowly). Administration: Subcutaneous injection weekly. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Retatrutide or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossSurvodutide
Clinical TrialsA dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
Weight LossCagrilintide
Clinical TrialsA long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Weight LossEloralintide
Clinical TrialsA next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Weight LossOrforglipron
FDAAn oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Weight LossWant updates on Retatrutide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.